BofA Securities reiterated its Buy rating on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), with a steady price target of GBP145.00. The firm's positive stance is based on the pharmaceutical giant's ...

Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...

Aerospace startup Boom says they've proven quiet supersonic flight is possible with their passenger airplanes after a ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...

How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...

Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.